Scribe Therapeutics Inc. (SCTX)

Scribe Therapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Scribe Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-35.73	-21.81	-47.79
Depreciation & Amortization	3.87	3.91	3.52
Share-Based Compensation	-	4.14	2.85
Other Operating Activities	-7.29	-31.46	-3.82
Operating Cash Flow	-39.15	-45.21	-45.24
Capital Expenditures	-0.8	-1.27	-1.35
Change in Investments	-	46.54	14.36
Investing Cash Flow	39.9	45.27	13.01
Share Issuance / Repurchase	-	0.14	0.47
Other Financing Activities	-0.27	-	-0.69
Financing Cash Flow	-0.27	0.14	-0.22
Net Cash Flow	0.48	0.19	-32.44
Free Cash Flow	-39.94	-46.48	-46.58
Free Cash Flow Margin	-110.09%	-90.83%	-169.93%